Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
CUDC-101 is a novel, small-molecule, anticancer agent targeting histone deacetylase (HDAC), EGF receptor (EGFR), and HER2. It is currently in phase I clinical development in patients with solid tumors. Previously, we reported that CUDC-101 has potent antiproliferative and proapoptotic activity in cultured tumor cells and in vivo xenograft models. We now show that cancer cells that have acquired resistance to single-target EGFR inhibitors through upregulation of AXL or loss of E-cadherin remain sensitive to CUDC-101, which inhibits MET- and AXL-mediated signaling, restores E-cadherin expression, and reduces cell migration. CUDC-101 also efficiently inhibited the proliferation of MET-overexpressing non–small cell lung cancer and gastric cancer cell lines and inhibited the migration and invasion of invasive tumor cells. Taken together, these results suggest that coupling HDAC and HER2 inhibitory activities to an EGFR inhibitor may potentially be effective in overcoming drug resistance and preventing cancer cell migration. Mol Cancer Ther; 12(6); 925–36. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499 · cited 1×
“Results from both preclinical studies in tumor cell lines and clinical trials have identified MET pathway activation as an important mechanism of resistance to EGFR inhibitors with MET amplification being responsible for 5% to 20% of cases of resistance in NSCLC (8, 19, 20).”
BackgroundKris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517 · cited 1×
“In addition, those patients who achieve clinical benefit typically develop drug resistance (1-3).”
BackgroundBean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598 · cited 1×
“Results from both preclinical studies in tumor cell lines and clinical trials have identified MET pathway activation as an important mechanism of resistance to EGFR inhibitors with MET amplification being responsible for 5 to 20% of cases of resistance in NSCLC (8, 19, 20).”
BackgroundActivation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224 · cited 20×
“Although the mechanism of AXL overexpression is unknown, recent studies examining AXL overexpression-mediated EGFR inhibitor resistance in NSCLC cells found that AXL was not amplified or mutated (15), suggesting that AXL may be upregulated at the transcriptional level, perhaps by epigenetic mechanisms.”
BackgroundInfluentialNovel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL
Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., Halsey, W., Sathe, G. M., Martin, A.-M., & Gilmer, T. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4490 · Cited by 495 · cited 1×
“Overexpression of AXL has been reported as a mechanism of acquired lapatinib resistance in breast cancer cells (49), acquired imatinib resistance in gastrointestinal stromal tumors (50), and most recently erlotinib resistance in NSCLC cells and patient specimens (15).”
Background
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Chen, P., Huang, H.-P., Wang, Y., Jin, J., Long, W.-G., Chen, K., Zhao, X.-H., Chen, C.-G., & Li, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1234-8 · Cited by 161
Liffers, K., Kolbe, K., Westphal, M., Lamszus, K., & Schulte, A. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0372-y · Cited by 41
Recent advances of dual FGFR inhibitors as a novel therapy for cancer
Liang, Q., Wang, J., Zhao, L., Hou, J., Hu, Y., & Shi, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113205 · Cited by 32
Self-citation
Metadata
- Authors
- Wang, J., Pursell, N. W., Samson, M. E. S., Atoyan, R., Ma, A. W., Selmi, A., Xu, W., Cai, X., Voi, M., Savagner, P., & Lai, C.-J.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-06-01
- Volume
- 12
- Issue
- 6
- Pages
- 925-936
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2164868034
- Cited by
- 82
- References
- 5
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-1045
- The paper
- Wang, J., Pursell, N. W., Samson, M. E. S., Atoyan, R., Ma, A. W., Selmi, A., Xu, W., Cai, X., Voi, M., Savagner, P., & Lai, C.-J. (2013). Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-1045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.